BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma

被引：42

作者：

Gonzalez-Campora, Ricardo ^{[1
]}

Davalos-Casanova, Guillermo

Beato-Moreno, Antonio

Garcia-Escudero, Antonio

Pareja Megia, Maria Jesus

Montironi, Rodolfo

Lopez-Beltran, Antonio

机构：

[1] Virgen Macarena Univ Hosp, Dept Pathol, Seville, Spain

[2] Univ Seville, Sch Med, Seville, Spain

[3] San Carlos Mil Hosp, Urol Serv, Cadiz, Spain

[4] San Carlos Mil Hosp, Dept Stat & Operat Res, Cadiz, Spain

[5] Polytech Univ Marche Reg, Inst Pathol Anat & Histopathol, Ancona, Italy

[6] Univ Cordoba, Sch Med, Reina Sofia Univ Hosp, Dept Pathol, Cordoba, Spain

来源：

CANCER LETTERS | 2007年 / 250卷 / 02期

关键词：

TP53; BCL-2; BAX; bladder cancer;

D O I：

10.1016/j.canlet.2006.10.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Whether TP53, BCL-2 and BAX expressions add independent prognostic information in patients with Ta/Tlbladder urothelial carcinoma remains unclear. TP53 overexpression correlated with high tumor grade (p = 0.004), WHO grading categories (0.045), BAX expression (p = 0.043) and pathologic stage (p = 0.05). BCL-2 immunostaining was inverse associated with tumor grade (p = 0.008). Lack of BAX expression was related to reduced patient's survival (p = 0.028). Mortality was higher in patients with BCL-2+/TP53+ (p = 0.023) or TP53+/BAX- (p = 0.027) phenotype. BAX and pathologic stage were independent predictors of progression-free and overall survival, respectively. Therefore, BAX expression might be relevant in patient's prognosis. (c) 2006 Elsevier Ireland Ltd. All rights reserved.

引用

页码：292 / 299

页数：8

共 37 条

[1] Apoptosis in transitional cell carcinoma of bladder and its relation to proliferation and expression of P53 and Bcl-2 [J].

Amirghofran, Z ;

Monabati, A ;

Khezri, A ;

Malek-Hosseini, Z .

PATHOLOGY & ONCOLOGY RESEARCH, 2004, 10 (03) :154-158

[2] Bcl-2 and p53 overexpression as associated risk factors in transitional cell carcinoma of the bladder [J].

Atuǧ F. ;

Türkeri L. ;

Özyürek M. ;

Akdaş A. .

International Urology and Nephrology, 1998, 30 (4) :455-461

[3] Prognostic value of Bcl-2 and p53 expression in urinary tract transitional cell cancer [J].

Bilim, V ;

Tomita, Y ;

Kawasaki, T ;

Katagiri, A ;

Imai, T ;

Takeda, M ;

Takahashi, K .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (10) :686-688

[4] Variable Bcl-2 phenotype in benign and malignant lesions of urothelium [J].

Bilim, VN ;

Tomita, Y ;

Kawasaki, T ;

Takeda, M ;

Takahashi, K .

CANCER LETTERS, 1998, 128 (01) :87-92

[5]

Casetta G, 1997, EUR UROL, V32, P229

[6]

DAAS M, 1995, ANN M TOR

[7]

Dahse R, 2000, ONCOL REP, V7, P931

[8]

Gazzaniga P, 1998, ONCOL REP, V5, P901

[9] Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications [J].

Giannopoulou, I ;

Nakopoulou, L ;

Zervas, A ;

Lazaris, AC ;

Stravodimos, C ;

Giannopoulos, A ;

Davaris, PS .

UROLOGICAL RESEARCH, 2002, 30 (05) :342-345

[10] Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder [J].

Glick, SH ;

Howell, LP ;

White, RWD .

JOURNAL OF UROLOGY, 1996, 155 (05) :1754-1757

← 1 2 3 4 →